Member Since 2023
About my Start-up

bYoRNA comes from a breakthrough technology allowing the bioproduction of mRNA, more particularly messenger RNA (mRNA) or long non-coding RNA ( IncRNA ), by recombinant yeast, which constitutes a complete paradigm shift compared to the current in vitro production ( IVT) approach.

The particularity of the technology is that it manages to avoid the degradation of messenger RNA within the cytoplasm of yeast cells by accumulating it in specific sub-compartments, which recognize and accumulate the RNA of interest. The technology therefore makes it possible to produce the RNA of interest in large quantities in yeast cells, whereas this is not normally possible, as the messenger RNA is degraded too quickly.

Messenger RNA is currently manufactured in vitro through enzymatic synthesis. This is an expensive process, with a complex supply chain requiring many IP-protected enzymes. One kilogram of mRNA currently costs more than 30M€ to produce. We want to produce locally longer, better mRNAs for less than 1M€ per kg.

We have already improved by 30 the titer of the our initial proof-of-concept and we have signed a co-development agreement with a NASDAQ bioproduction company.

Why your idea is a “winner"?:

bYoRNA will divide by 100 the production cost of high-quality mRNA to help fight pandemics, cancers and genetic diseases. We have already produced a few milligrams of mRNA in eucaryotic cells.

What is your current or intended business/revenue model?:

Production in-house of pre-clinical, non-GMP batches.
Outsourcing of GMP production to approved CDMOs (big pharma suppliers) and 8% royalties for clinical and approved drugs.

Do you have any Patent or IP registered (related to the solution that you are looking for an investment)?:

We are currently filing our own patent to protect the technology in yeast cells. We are working with ICOSA, one of the main life science IP consultancies in France. We have also signed a co-development agreement with DYADIC, a key NASDAQ bioproduction player, to adapt our technology to the second-best eucaryotic organism after yeast, and we will file an additional patent for this organism once we get the new experimental results.

Has your technology already been implemented in any field/sector?:

Not yet. But the main idea is the one currently used to produce most of the industrial and pharmaceutical proteins available worldwide. We adapted it to the production of mRNA thanks to a disruptive innovation.

Which market and customer need(s)/problem(s) is (are) your products(s)/service(s) going to solve?:

- scale: ability to produce 10,000 times more mRNA for protein replacement / metabolic / rare diseases.
- mRNA length: ability to produce self-amplifying RNAs, which are 6 times longer than normal mRNAs and cannot be produced at scale with the current in vitro technology.
- reliability: our production facilities will be implanted locally with few needs for exotic, expensive and supply-chain exposed enzymes, which make them the production tool of choice in case of crisis.

- 18B$ cancer (200 potential customers)
- 4B$ human vaccines (200 potential customers)
- 1B$ veterinary vaccines (20 potential customers)
- 12B$ protein replacement (400 potential customers)
The number of potential customers is based on the current number of RNA clinical and pre-clinical trials. The market size is based on the COGS of current drug markets, considering the disruptive potential of mRNA therapies (for example, survival rate x5 for Phase I clinical trials of BioNTech pancreatic cancer vaccine).

TRL 4 – technology validated in lab
Candidate Overview

Log in

Sign Up

Forgotten Password